These observations suggest that aberrant hyperfunction of ADCY1 in FXS is a potential therapeutic target, through which the pathological overactivation of both ERK1⁄2 and Akt signaling pathways can be corrected. The gene discussed is AKT1; the disease is fragile X syndrome.